Your browser doesn't support javascript.
loading
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.
Blumencranz, Peter; Habibi, Mehran; Shivers, Steve; Acs, Geza; Blumencranz, Lisa E; Yoder, Erin B; van der Baan, Bastiaan; Menicucci, Andrea R; Dauer, Patricia; Audeh, William; Cox, Charles E.
Afiliação
  • Blumencranz P; BayCare Oncology, Clearwater, FL, USA.
  • Habibi M; Johns Hopkins University, Baltimore, MD, USA.
  • Shivers S; Comprehensive Breast Cancer Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Acs G; Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Blumencranz LE; Agendia, Inc., Irvine, CA, USA.
  • Yoder EB; Agendia, Inc., Irvine, CA, USA.
  • van der Baan B; Agendia, NV, Amsterdam, The Netherlands.
  • Menicucci AR; Agendia, Inc., Irvine, CA, USA.
  • Dauer P; Agendia, Inc., Irvine, CA, USA.
  • Audeh W; Agendia, Inc., Irvine, CA, USA. william.audeh@agendia.com.
  • Cox CE; Comprehensive Breast Cancer Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Ann Surg Oncol ; 30(13): 8353-8361, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37658272
ABSTRACT

BACKGROUND:

Neoadjuvant chemotherapy (NCT) increases the feasibility of surgical resection by downstaging large primary breast tumors and nodal involvement, which may result in surgical de-escalation and improved outcomes. This subanalysis from the Multi-Institutional Neo-adjuvant Therapy MammaPrint Project I (MINT) trial evaluated the association between MammaPrint and BluePrint with nodal downstaging. PATIENTS AND

METHODS:

The prospective MINT trial (NCT01501487) enrolled 387 patients between 2011 and 2016 aged ≥ 18 years with invasive breast cancer (T2-T4). This subanalysis includes 146 patients with stage II-III, lymph node positive, who received NCT. MammaPrint stratifies tumors as having a Low Risk or High Risk of distant metastasis. Together with MammaPrint, BluePrint genomically (g) categorizes tumors as gLuminal A, gLuminal B, gHER2, or gBasal.

RESULTS:

Overall, 45.2% (n = 66/146) of patients had complete nodal downstaging, of whom 60.6% (n = 40/66) achieved a pathologic complete response. MammaPrint and combined MammaPrint and BluePrint were significantly associated with nodal downstaging (p = 0.007 and p < 0.001, respectively). A greater proportion of patients with MammaPrint High Risk tumors had nodal downstaging compared with Low Risk (p = 0.007). When classified with MammaPrint and BluePrint, more patients with gLuminal B, gHER2, and gBasal tumors had nodal downstaging compared with HR+HER2-, gLuminal A tumors (p = 0.538, p < 0.001, and p = 0.013, respectively).

CONCLUSIONS:

Patients with genomically High Risk tumors, defined by MammaPrint with or without BluePrint, respond better to NCT and have a higher likelihood of nodal downstaging compared with patients with gLuminal A tumors. These genomic signatures can be used to select node-positive patients who are more likely to have nodal downstaging and avoid invasive surgical procedures.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Ann Surg Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Ann Surg Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos